The drug is a new Category 1.1 antitumor drug developed by the Chinese pharmaceutical company Nanjing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Its clinical trials are already underway for a variety of cancers, including non-small cell lung cancer, soft tissue sarcoma, gastric cancer, colorectal cancer, medullary thyroid cancer, differentiated thyroid cancer, and esophageal squamous cancer.

Anlotinib hydrochloride was approved for marketing under the trade name FuKeWei® by the NMPA on May 9, 2018 for the third-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The fast time to market of anlotinib hydrochloride was made possible by the Chinese government’s support for accelerated evaluation and approval of innovative drugs.

According to CRI’s market research, as of September 2021, anlotinib has been approved in China for four indications: (1) advanced NSCLC (2) soft tissue sarcomas (3) small cell lung cancer (4) advanced or metastatic medullary thyroid cancer.

In 2020, there were 4.57 million new cancer cases in China, 820,000 of which were lung cancer cases. Lung cancer is mainly divided into small cell lung cancer and non-small cell lung cancer (NSCLC), and the latter accounts for about 80-85% among all patients with lung cancer, most of which are diagnosed as locally advanced or metastatic disease.

Soft tissue sarcomas are a group of rare cancers with a low incidence that account for only 1% of all malignancies. But it is characterized by high evolution possibility, poor prognosis, high insidiousness, and inconspicuous early symptoms, making it extremely difficult to treat clinically.

According to CRI’s estimation, there were about 220,000 new cases of thyroid cancer in China in 2020, among which medullary thyroid carcinoma (MTC) accounts for about 2%-4%. MTC is more likely to have malignant evolution and distant metastasis, and the treatment may not impose good effects for patients with advanced stage.

According to CRI’s market research, the sales value of anlotinib in the Chinese market was approximately CNY922 million (USD142 million) in 2020, with a CAGR of 444% from 2018 to 2020. Generic drugs of anlotinib from other Chinese pharmaceutical companies are expected to be on the market around 2024, so China’s anlotinib market will remain fully occupied by Chia Tai Tianqing Pharmaceutical’s product till 2025.

CRI expects that China’s anlotinib market will continue to grow from 2021 to 2025 as new cancer cases are expected to increase in China due to environmental pollution and lifestyle changes.

Topics Covered:

• Impact of COVID-19 on China’s Anlotinib Hydrochloride Market?
• The Incidence of Cancers in China?
• Development Environment of Anlotinib Hydrochloride in China?
• Sales Volume of Anlotinib Hydrochloride in China?
• Sales Volume and Value of Anlotinib Hydrochloride in China by Region?
• Major Anlotinib Hydrochloride Manufacturers in China and Their Market Shares?
• Sales Price of Anlotinib Hydrochloride in China?
• Major Anlotinib Hydrochloride Producers in China?
• Prospects of China’s Anlotinib Hydrochloride Market, 2021-2025?

Global Medication Management Market: Market Segments: By Software Type (CPOE, CDSS, Medication Administration Software, Inventory Management, ADS, and Others); By Service (Medication Analytics Services, ADE Surveillance Services, and Point-Of-Care Verification Services); By Mode of Delivery (Web-Based, Cloud-Based and On-Premises); By End User (Hospitals, Pharmacy, and Others); and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

The post Research Report on China’s Anlotinib Hydrochloride Market, 2021-2025 first appeared on CRI Report.